<DOC>
	<DOCNO>NCT00274092</DOCNO>
	<brief_summary>The objective study compare bronchodilator efficacy safety tiotropium inhalation capsule ( 18 mcg daily ) Atrovent MDI ( 2 puff 20 mcg q.i.d . ) patient chronic obstructive pulmonary disease ( COPD )</brief_summary>
	<brief_title>Efficacy Safety Tiotropium Inhalation Capsules Atrovent MDI Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>This randomize , double-blind , double-dummy , parallel group study compare bronchodilator efficacy safety tiotropium inhalation capsule Atrovent MDI patient chronic obstructive pulmonary disease ( COPD ) . Following initial screen visit , patient enter 2-week baseline period . Patients successfully complete phase randomize double-blind portion study receive tiotropium daily ( morning ) Atrovent four time daily . Pulmonary function test conduct prior start therapy Visit 2 ( i.e . randomization visit completion 2-week run-in period ) 120 minute post-dosing . Pulmonary function test repeated time interval end therapy . Study Hypothesis : Null alternative hypotheses The primary objective study address two-sided test 0.05 level significance null hypothesis , patient chronic obstructive pulmonary disease ( COPD ) , bronchodilator efficacy one month great tiotropium inhalation capsule ( 18mcg daily ) ATROVENT MDI ( 2 puff 20 mcg q.i.d . ) , alternative hypothesis bronchodilator efficacy great tiotropium inhalation capsule ( 18 mcg daily ) . Comparison ( ) : Trough FEV1 response analyze . Peak FEV1 , FVC trough peak response , number Rescue Medication change baseline total score Patient Evaluation Questionnaire analyze . Change baseline category score Patient Evaluation Questionnaire also analyze .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion : 1 . COPD patient Forced Expiratory Volume one second ( FEV1 ) &lt; = 65 % predict normal FEV1 &lt; = 70 % Forced Vital Capacity ( FVC ) . 2 . Male female patient 40 year age old . 3 . Patients must smoke history 10 packyears . A packyear defined equivalent smoke one pack cigarettes per day year . 4 . Patients must able perform pulmonary function test require protocol . 5 . Patients must able inhale medication HandiHaler device good technique inhale aerosol administer MDI.. 6 . All patient must sign Informed Consent Form prior participation trial i.e. , prior prestudy washout usual pulmonary medication . Exclusion : 1 . Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study . 2 . Patients clinically significant abnormal baseline hematology , blood chemistry urinalysis , abnormality defines disease list exclusion criterion exclude . 3 . All patient SGOT SGPT twice upper normal limit , bilirubin 150 % creatinine 125 % upper normal limit exclude regardless clinical condition . Repeat laboratory evaluation conduct subject . 4 . Patients recent history ( i.e . one year less ) myocardial infarction . 5 . Any unstable life threaten cardiac arrhythmia cardiac arrhythmia require intervention change drug therapy within past year . 6 . Patients regular use daytime oxygen therapy . 7 . Patients know active tuberculosis . 8 . Patients history cancer within last five year . Patients treat basal cell carcinoma allow . 9 . Patients history lifethreatening pulmonary obstruction , history cystic fibrosis bronchiectasis . 10 . A history thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per Exclusion 1 . 11 . Patients upper respiratory tract infection past 6 week prior Screening Visit ( =Visit 1 ) baseline period 2weeks ( runin period ) . 12 . Patients know hypersensitivity anticholinergic drug , lactose component inhalation capsule delivery system . 13 . Patients know symptomatic prostatic hypertrophy bladder neck obstruction . ( Patients BPH medication minimum symptom permit ) . 14 . Patients know narrowangle glaucoma . 15 . Patients treat cromolyn sodium nedocromil sodium . 16 . Patients treat antihistamine . 17 . Patients use oral corticosteroid medication unstable dosage ( i.e . le 6 week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day . 18 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception ( e.g . oral contraceptive , intrauterine device , diaphragm ) . 19 . Patients history asthma , allergic rhinitis atopy blood total eosinophil count big equal 400 per ul ( male ) bigger/equal 320 per ul ( female ) . A repeat eosinophil count conduct patient . 20 . Patients history and/or active alcohol drug abuse . 21 . Patients take investigational drug one month six halflives ( whichever great ) prior Screening Visit ( =Visit 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>